Inventor · disambiguated record
Kenneth A. Thomas, Jr.
Also filed as: THOMAS JR KENNETH A · THOMAS KENNETH · THOMAS KENNETH A · THOMAS KENNETH A JR
32 granted patents·9 pending applications·985 citations·filing 1983–2024
98Inventor score
Files withMERCK & CO INC25VENTURIS THERAPEUTICS INC4CARDIOVASCULAR BIOTHERAPEUTICS INC3TREFOIL THERAPEUTICS INC2KENDALL RICHARD L1
Top patents by PatentIndex Score
41 records- 0195US5712380ADNA encoding a soluble VEGF inhibitorMERCK & CO INC·Filed 1994·Granted Jan 27, 1998·116 cites·5 claims
- 0294US6841367B2Human receptor tyrosine kinase, KDRMERCK & CO INC·Filed 2002·Granted Jan 11, 2005·36 cites·6 claims
- 0394US6359115B1Human receptor tyrosine kinase, KDRMERCK & CO INC·Filed 2000·Granted Mar 19, 2002·55 cites·6 claims
- 0494US4444760APurification and characterization of a protein fibroblast growth factorMERCK & CO INC·Filed 1983·Granted Apr 24, 1984·95 cites·8 claims
- 0593US8034772B2Inhibitor of vascular endothelial cell growth factorMERCK SHARP & DOHME·Filed 2009·Granted Oct 11, 2011·6 cites·4 claims
- 0693US6841382B2Human receptor tyrosine kinase, KDRMERCK & CO INC·Filed 2001·Granted Jan 11, 2005·31 cites·6 claims
- 0793US6235741B1Angiogenesis inhibitorsMERCK & CO INC·Filed 1998·Granted May 22, 2001·73 cites·3 claims
- 0893US6204011B1Human receptor tyrosine kinase, KDRMERCK & CO INC·Filed 1998·Granted Mar 20, 2001·84 cites·26 claims
- 0992US7071159B2Inhibitor of vascular endothelial cell growth factorMERCK & CO INC·Filed 2002·Granted Jul 4, 2006·33 cites·4 claims
- 1090US5861484AInhibitor of vascular endothelial cell growth factorMERCK & CO INC·Filed 1997·Granted Jan 19, 1999·63 cites·4 claims
- 1189US6933134B2DNA molecules encoding vascular endothelial cell growth factor II subunitsMERCK & CO INC·Filed 2002·Granted Aug 23, 2005·15 cites·16 claims
- 1288US10966610B2Angiogenic treatment of ischemic heart diseaseCARDIOVASCULAR BIOTHERAPEUTICS INC·Filed 2017·Granted Apr 6, 2021·5 cites·15 claims
- 1388US6569434B1Vascular endothelial cell growth factor C subunitMERCK & CO INC·Filed 2000·Granted May 27, 2003·19 cites·1 claims
- 1488US6375929B1Gene therapy for inhibition of angiogenesisMERCK & CO INC·Filed 1999·Granted Apr 23, 2002·98 cites·6 claims
- 1586US5994300AVascular endothelial cell growth factor C subunitMERCK & CO INC·Filed 1993·Granted Nov 30, 1999·50 cites·7 claims
- 1679US6380203B1Angiogenesis inhibitorsMERCK & CO INC·Filed 1998·Granted Apr 30, 2002·24 cites·14 claims
- 1777US5726152AVascular endothelial cell growth factor IIMERCK & CO INC·Filed 1994·Granted Mar 10, 1998·33 cites·10 claims
- 1876US8983570B2Therapeutic angiogenesis for treatment of the spineSTEGMANN THOMAS J·Filed 2008·Granted Mar 17, 2015·2 cites·20 claims
- 1976US2024415932A1Systems and Methods for Angiogenic Treatment in Wound HealingVENTURIS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2075US11103553B2Modified fibroblast growth factors for the treatment of ocular disordersTREFOIL THERAPEUTICS INC·Filed 2014·Granted Aug 31, 2021·2 cites·5 claims
- 2172US6140073AVascular endothelial cell growth factor C subunitMERCK & CO INC·Filed 1996·Granted Oct 31, 2000·23 cites·21 claims
- 2268US10624952B2Systems and methods for angiogenic treatment in wound healingCARDIOVASCULAR BIOTHERAPEUTICS INC·Filed 2014·Granted Apr 21, 2020·0 cites·19 claims
- 2366US5409897ACysteine-modified acidic fibroblast growth factor and methods of useMERCK & CO INC·Filed 1994·Granted Apr 25, 1995·20 cites·18 claims
- 2466US5223483ACysteine-modified acidic fibroblast growth factorMERCK & CO INC·Filed 1992·Granted Jun 29, 1993·31 cites·22 claims
- 2564US5401832ABrain derived and recombinant acidic fibroblast growth factorMERCK & CO INC·Filed 1992·Granted Mar 28, 1995·23 cites·2 claims
- 2662US5532343APurification and characterization of a glioma-derived growth factor having vascular endothelial cell growth promoting activityMERCK & CO INC·Filed 1994·Granted Jul 2, 1996·13 cites·2 claims
- 2762US5338840ADNA encoding glioma-derived growth factor having vascular endothelial cell growth promoting activityMERCK & CO INC·Filed 1992·Granted Aug 16, 1994·13 cites·1 claims
- 2861US12168038B2Systems and methods for angiogenic treatment in wound healingVENTURIS THERAPEUTICS INC·Filed 2020·Granted Dec 17, 2024·0 cites·14 claims
- 2960US2021338777A1Modified fibroblast growth factors for the treatment of ocular disordersTREFOIL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3059US2007010442A1Inhibitor of vascular endothelial cell growth factorKENDALL RICHARD L·Filed 2006·Application pending·0 cites
- 3155US2021212565A1Angiogenic treatment of ischemic heart diseaseVENTURIS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3252US5806281ATear tape adapted for complete sealing of package overwrapKT IND INC·Filed 1996·Granted Sep 15, 1998·16 cites·7 claims
- 3350US2006057694A1Rat receptor tyrosine knase, kdrTHOMAS KENNETH A JR·Filed 2004·Application pending·0 cites
- 3443US2002065240A1Gene therapy for stimulation of angiogenesisMERCK & CO INC·Filed 2001·Application pending·0 cites
- 3542US2004101478A1In vivo methods of determining activity of receptor-type kinase inhibitorsFiled 2002·Application pending·0 cites
- 3641US11224635B2Therapeutic angiogenesis for treatment of the spine and other tissuesVENTURIS THERAPEUTICS INC·Filed 2013·Granted Jan 18, 2022·0 cites·15 claims
- 3740US2017296625A1Therapeutic angiogenesis for wound healingCARDIOVASCULAR BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3838US5312911ACysteine-modified acidic fibroblast growth factorMERCK & CO INC·Filed 1993·Granted May 17, 1994·5 cites·4 claims
- 3937US6228871B1Angiogenesis inhibitorsMERCK & CO INC·Filed 1999·Granted May 8, 2001·1 cites·27 claims
- 4033US6180107B1Vascular endothelial cell growth factor IIMERCK & CO INC·Filed 1998·Granted Jan 30, 2001·0 cites·5 claims
- 4131US2003165656A1Binder fiber for improved carpet appearance retention and endpointSOLUTIA INC·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kenneth A. Thomas, Jr. files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →